CAJ | 학술논문

罗格列酮和吡格列酮同属为噻唑烷二酮类胰岛素增敏剂，主要用于2型糖尿病的治疗。罗格列酮因可能增加心血管事件风险于2010年被限用（美国）或禁用（欧洲），2013年又因增加心血管事件风险证据不足被解禁。吡格列酮上市后的大型前瞻性临床研究和Meta分析结果显示，该药可以使2型糖尿病患者心肌梗死／中风／死亡的风险降低，从而被认为有心血管保护作用。罗格列酮和吡格列酮心血管风险的差异，可能与它们对2型糖尿病患者脂代谢影响的不同有关，也可能与其基因调控的不同有关。
라격렬동화필격렬동동속위새서완이동류이도소증민제，주요용우2형당뇨병적치료。라격렬동인가능증가심혈관사건풍험우2010년피한용（미국）혹금용（구주），2013년우인증가심혈관사건풍험증거불족피해금。필격렬동상시후적대형전첨성림상연구화Meta분석결과현시，해약가이사2형당뇨병환자심기경사／중풍／사망적풍험강저，종이피인위유심혈관보호작용。라격렬동화필격렬동심혈관풍험적차이，가능여타문대2형당뇨병환자지대사영향적불동유관，야가능여기기인조공적불동유관。
Rosiglitazone and pioglitazone belong to thiazolidinediones( TZD)insulin sensitizers, mainly used for the treatment of type 2 diabetes. Rosiglitazone was restricted to use or withdrawn from the market due to possibly increased cardiovascular events in 2010,and then was released for insufficient evidence in 2013. The large prospective clinical trial and Meta-analysis indicated that pioglitazone has cardiovascular protective effect,since the drug reduced risk of myocardial infarction/stroke/death of patients with type 2 diabetes. The different cardiovascular risk of rosiglitazone and pioglitazone maybe related to the differences in effect on lipid metabolism or in gene regulation.